Legislation targeting popular Chinese biotech contractors like WuXi AppTec wasn't included in must-pass defense legislation ...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday ...
BioAge Labs is scrapping a Phase 2 trial testing its anti-obesity drug, a few months after its flashy $198 million initial ...
The usual enhanced security measures are expected to be in place in San Francisco next month when the healthcare industry ...
Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, ...
AstraZeneca and Daiichi Sankyo have unveiled new data on their TROP2-directed ADC in pretreated lung cancer patients with ...
A UK political committee says the country is underprepared for future pandemics due to 'worrying developments' on domestic ...
The same day that National Resilience announced a new CEO, it said that it will cut more than 100 jobs in Florida. The ...
Wisconsin border in 'America's Dairyland,' Eli Lilly is staking one of its largest-ever manufacturing bets to continue its ...
GSK's BD team was busy leading up to the Thanksgiving holiday. In the last two days, the UK-based pharma has announced three ...
Johnson & Johnson has filed for two new pediatric indications as it looks to position its blockbuster immunotherapy Tremfya ...
GSK revises deal with Chongqing Zhifei Biological Products, extending Shingrix distribution rights in China through 2034 but ...